Post Profile






No difference in death rates among patients exposed to common rheumatoid arthritis drugs

onfirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). This population-based study of RA patients in Sweden—the first to compare mortality rates among patients treated with individual TNF inhibitors—is now available in Arthritis & Rheumatism, a journal published by Wiley on behalf of the American College of Rheumatology (ACR).
read more

share

Related Posts


What Is Remicade (infliximab)?

Health : Medical News Today

Remicade (infliximab) is a TNF inhibitor, a monoclonal antibody against tumor necrosis factor alpha (TNF-α), that is prescribed for the treatment of several autoimmune inflammatory diseases, including rheumatoid arthritis, chronic ...

MabThera(rituximab) Is More Effective In Treating Rheumatoid Arthritis Than Switching Patients To A Second Anti-TNF

Health : Medical News Today

New data1 presented at the European League Against Rheumatism (EULAR) annual meeting revealed that when rheumatoid arthritis (RA) patients do not respond to a TNF inhibitor, a commonly used class of drugs in RA, it is more effective...

What Is Humira (adalimumab)

Health : Medical News Today

Humira (adalimumab) is a TNF inhibitor approved for the treatment of rheumatoid arthritis, chronic plaque psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis. Humi...

Arthritis patients taking newer treatments do not have an overall increased cancer risk, research finds

Academics / General Science : Science Daily

Newer biologic treatments, including infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), golimumab (Simponi) and etanercept (Enbrel), used in patients with arthritis do not increase the risk of cancer, according...

Rheumatoid Arthritis Drugs: Study Compares Overall Mortality In TNF Inhibitors: Humira, Enbrel, And Remicade

Health : Medical News Today

New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and in...

Comments



Copyright © 2015 Regator, LLC